Harmony Biosciences Holdings (HRMY) Hisse Özeti
Ticari aşamada bir ilaç şirketi olan Harmony Biosciences Holdings, Inc. Amerika Birleşik Devletleri'nde nadir görülen nörolojik hastalıkları olan hastalar için tedaviler geliştirmeye ve ticarileştirmeye odaklanmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 4/6 |
| Gelecekteki Büyüme | 1/6 |
| Geçmiş Performans | 2/6 |
| Finansal Sağlık | 6/6 |
| Temettüler | 0/6 |
Ödüller
Risk Analizi
Risk kontrollerimizden HRMY için herhangi bir risk tespit edilmedi.
HRMY Community Fair Values
Create NarrativeSee what 168 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Harmony Biosciences Holdings, Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$35.47 |
| 52 Haftanın En Yüksek Seviyesi | US$40.87 |
| 52 Haftanın En Düşük Seviyesi | US$25.52 |
| Beta | 0.97 |
| 1 Aylık Değişim | 12.28% |
| 3 Aylık Değişim | 26.63% |
| 1 Yıllık Değişim | 12.25% |
| 3 Yıllık Değişim | 1.81% |
| 5 Yıllık Değişim | 19.19% |
| Halka arzdan bu yana değişim | -4.16% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Jun 19
HRMY: Patent Litigation Resolution Will Support Rare Neurology Pipeline Upside
Harmony Biosciences Holdings' analyst price target has been raised by $10, as analysts point to a major positive development in patent litigation and view recent share weakness as excessive, given updated expectations around growth, profitability, and future P/E assumptions. Analyst Commentary on Harmony Biosciences Holdings Stock Recent Street research on Harmony Biosciences Holdings centers on the patent litigation update, the reset in expectations around growth and profitability, and how these factors feed into updated valuation frameworks and P/E assumptions.Anlatı Güncellemesi • Jun 04
HRMY: Patent Litigation Resolution And Rare Neurology Pipeline Will Drive Future Upside
Analysts have lifted their price target on Harmony Biosciences Holdings to $75.49 from $62.00, citing recent patent litigation updates, views that prior share price weakness related to intellectual property concerns was excessive, and refreshed assumptions for revenue growth, profit margins, discount rate, and future P/E. Analyst Commentary Bullish analysts are framing the recent patent litigation update as a key clearing event for Harmony Biosciences Holdings, arguing that a major source of uncertainty has now been reduced.
Anlatı Güncellemesi • May 17
HRMY: Future Franchise Balance Will Reflect Patent Risks And Pediatric Expansion
Analysts recently lifted the fair value estimate for Harmony Biosciences Holdings to $28.00 from $25.00, citing updated views on patent litigation risks, intellectual property overhang, and longer term Wakix cash flow scenarios. These updates are reflected in slightly higher discount rates, modestly weaker revenue growth assumptions, a higher profit margin outlook, and a small change in future P/E expectations.Analiz Makalesi • May 14
Investors Can Find Comfort In Harmony Biosciences Holdings' (NASDAQ:HRMY) Earnings Quality
Harmony Biosciences Holdings, Inc.'s ( NASDAQ:HRMY ) earnings announcement last week didn't impress shareholders...Recent updates
Anlatı Güncellemesi • Jun 19
HRMY: Patent Litigation Resolution Will Support Rare Neurology Pipeline Upside
Harmony Biosciences Holdings' analyst price target has been raised by $10, as analysts point to a major positive development in patent litigation and view recent share weakness as excessive, given updated expectations around growth, profitability, and future P/E assumptions. Analyst Commentary on Harmony Biosciences Holdings Stock Recent Street research on Harmony Biosciences Holdings centers on the patent litigation update, the reset in expectations around growth and profitability, and how these factors feed into updated valuation frameworks and P/E assumptions.Anlatı Güncellemesi • Jun 04
HRMY: Patent Litigation Resolution And Rare Neurology Pipeline Will Drive Future Upside
Analysts have lifted their price target on Harmony Biosciences Holdings to $75.49 from $62.00, citing recent patent litigation updates, views that prior share price weakness related to intellectual property concerns was excessive, and refreshed assumptions for revenue growth, profit margins, discount rate, and future P/E. Analyst Commentary Bullish analysts are framing the recent patent litigation update as a key clearing event for Harmony Biosciences Holdings, arguing that a major source of uncertainty has now been reduced.Anlatı Güncellemesi • May 17
HRMY: Future Franchise Balance Will Reflect Patent Risks And Pediatric Expansion
Analysts recently lifted the fair value estimate for Harmony Biosciences Holdings to $28.00 from $25.00, citing updated views on patent litigation risks, intellectual property overhang, and longer term Wakix cash flow scenarios. These updates are reflected in slightly higher discount rates, modestly weaker revenue growth assumptions, a higher profit margin outlook, and a small change in future P/E expectations.Analiz Makalesi • May 14
Investors Can Find Comfort In Harmony Biosciences Holdings' (NASDAQ:HRMY) Earnings Quality
Harmony Biosciences Holdings, Inc.'s ( NASDAQ:HRMY ) earnings announcement last week didn't impress shareholders...Analiz Makalesi • May 11
Harmony Biosciences Holdings, Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next
As you might know, Harmony Biosciences Holdings, Inc. ( NASDAQ:HRMY ) last week released its latest first-quarter, and...Seeking Alpha • Apr 21
Harmony Biosciences: Four More Wakix Years, Nothing Visible Beyond
Summary Harmony Biosciences is a profitable, single-asset company built on Wakix, generating nearly $1B in annual revenue with strong margins and cash reserves. Despite robust growth and patent runway for Wakix through at least 2030, HRMY has failed to develop or acquire a credible pipeline asset. The market prices HRMY at discounted multiples (~11x earnings, ~1.3x EV/sales), reflecting skepticism about future growth beyond Wakix. I view HRMY as fully valued and recommend a Sell until clear evidence emerges of successful capital deployment into a durable second pillar. Read the full article on Seeking AlphaAnlatı Güncellemesi • Apr 21
HRMY: Patent Trial Outcome And Exclusivity Timeline Will Drive Future Upside
Harmony Biosciences' blended analyst price target has moved lower into a $28 to $36 range, as analysts factor in updated Wakix patent trial commentary, the possibility of earlier generic entry, and reduced confidence in retaining cash flows past 2028. Analyst Commentary Recent research updates have generally moved toward more cautious stances on Harmony Biosciences, with several firms cutting price targets and shifting ratings to Hold or Underperform.Anlatı Güncellemesi • Apr 06
HRMY: Earlier Patent Setback Risk Will Drive Bearish Franchise Repricing
Harmony Biosciences Holdings' latest narrative update reflects a steady fair value estimate alongside a reset in Street price targets, with several analysts trimming their views into a $28 to $36 range as they factor in increased Wakix patent uncertainty and the potential timing of generic entries. Analyst Commentary Recent research updates cluster around a more cautious stance on Harmony Biosciences, with several bearish analysts trimming price targets into the US$28 to US$36 band and shifting ratings toward more neutral positions.Anlatı Güncellemesi • Mar 23
HRMY: Patent Trial Outcomes Will Shape Future Upside Potential
Narrative Update on Harmony Biosciences Holdings The analyst price target range for Harmony Biosciences has been revised lower, with recent cuts to $30, $36 and $28 as analysts factor in increased Wakix patent uncertainty, potential earlier generic entry, and more conservative assumptions around long term cash flows and exclusivity. Analyst Commentary Recent Street research has leaned more cautious on Harmony Biosciences, with several firms trimming price targets and, in some cases, lowering ratings following developments in Wakix patent litigation and updated cash flow assumptions.Anlatı Güncellemesi • Mar 09
HRMY: Earlier Generic Threat To Key Franchise Will Drive Share Repricing
Analysts have reduced their average price target on Harmony Biosciences to $25 from $31. They cite higher perceived patent and exclusivity risks around Wakix, along with more conservative assumptions for long term cash flows and future P/E levels.
Anlatı Güncellemesi • Feb 23
HRMY: Legal Overhang On Key Sleep Franchise Will Shape Future Upside
Analysts have modestly lifted their fair value estimate for Harmony Biosciences Holdings from about $46.45 to roughly $47.30, while highlighting legal and generic entry risks to the Wakix franchise and reflecting these concerns in more cautious price targets and ratings. Analyst Commentary Recent Street research around Harmony Biosciences focuses heavily on legal outcomes for Wakix and the timing of potential generic entry, with valuation work and ratings increasingly framed through that risk lens.Anlatı Güncellemesi • Feb 09
HRMY: Sleep Disorder Pipeline And 2025 Outlook Will Support Future Upside
Analysts have trimmed their price target on Harmony Biosciences Holdings to US$45 from US$48, reflecting updated modeling while maintaining that their fundamental outlook for the business from 2025 remains intact. Analyst Commentary Analysts see the revised US$45 price target as a fine tuning of their models rather than a shift in their core stance on Harmony Biosciences Holdings from 2025 onward.Anlatı Güncellemesi • Jan 25
HRMY: Long-Term Sleep Disorder Pipeline Will Drive Future Upside Potential
Narrative Update The analyst price target for Harmony Biosciences Holdings has been revised slightly higher to about $46.45 from roughly $44.55, as analysts refresh their models to reflect updated sales ramps, guidance tweaks, and modestly adjusted long term assumptions for discount rates, margins, and P/E multiples. Analyst Commentary Recent research on Harmony Biosciences Holdings reflects a mix of optimism around execution and caution on valuation and growth durability, which helps explain why the average price target has shifted only modestly.Anlatı Güncellemesi • Jan 11
HRMY: Raised Guidance And Product Pipeline Progress Will Support Bullish Upside Potential
Analysts have slightly reduced their price targets on Harmony Biosciences Holdings, with moves such as Truist trimming its target to $45 from $48 and BofA nudging its target to $32 from $31. They cited updated models that reflect modestly adjusted sales ramps and guidance, while keeping core views on the business intact.Anlatı Güncellemesi • Dec 26
HRMY: Raised Guidance And Strengthening Launch Ramp Will Support Bullish Upside Potential
Analysts have raised their price target on Harmony Biosciences Holdings by $1 to $32, citing a slightly stronger near term launch ramp and 2% upward revisions to Wakix sales forecasts through 2027. Analyst Commentary Bullish analysts point to the improved price target as evidence that execution on the current launch is tracking slightly ahead of prior expectations.Anlatı Güncellemesi • Dec 12
HRMY: Raised Guidance And Core Franchise Strength Will Support Bullish Upside Potential
Analysts have modestly lowered their fair value estimate for Harmony Biosciences Holdings to $62.00 from $70.00, citing tempered long term revenue growth and profit margin expectations, despite slightly higher near term Wakix sales forecasts and recent price target revisions on the Street. Analyst Commentary Bullish analysts acknowledge that the modest trimming of fair value largely reflects more conservative long term assumptions, while near term fundamentals remain resilient.Analiz Makalesi • Nov 20
A Piece Of The Puzzle Missing From Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) 28% Share Price Climb
Harmony Biosciences Holdings, Inc. ( NASDAQ:HRMY ) shareholders are no doubt pleased to see that the share price has...Anlatı Güncellemesi • Sep 26
Expanding Sleep And Rare Disease Markets Will Unlock Future Potential
Analysts have reduced Harmony Biosciences’ price target from $50.45 to $44.55, citing negative Phase 3 data for ZYN002 in fragile X syndrome and competitive risks to Wakix, though future catalysts remain, resulting in a more cautious near-term outlook. Analyst Commentary Negative Phase 3 data for ZYN002 in fragile X syndrome raises concerns over Harmony's near-term growth prospects, compounded by the absence of detailed management commentary.Analiz Makalesi • Sep 11
A Piece Of The Puzzle Missing From Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) Share Price
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 19x, you may...Analiz Makalesi • Jun 26
Harmony Biosciences Holdings (NASDAQ:HRMY) Seems To Use Debt Rather Sparingly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analiz Makalesi • May 20
A Piece Of The Puzzle Missing From Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) 26% Share Price Climb
Those holding Harmony Biosciences Holdings, Inc. ( NASDAQ:HRMY ) shares would be relieved that the share price has...Analiz Makalesi • May 13
Why Harmony Biosciences Holdings' (NASDAQ:HRMY) Earnings Are Better Than They Seem
Shareholders appeared to be happy with Harmony Biosciences Holdings, Inc.'s ( NASDAQ:HRMY ) solid earnings report last...Analiz Makalesi • May 09
Results: Harmony Biosciences Holdings, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Shareholders of Harmony Biosciences Holdings, Inc. ( NASDAQ:HRMY ) will be pleased this week, given that the stock...Seeking Alpha • Mar 24
Harmony Biosciences: A Compelling Risk-Reward Opportunity
Summary Harmony Biosciences offers a promising investment with one commercial drug, WAKIX, and a robust pipeline, despite some setbacks and risks. The company’s financial health is strong, with significant cash reserves and manageable debt, supporting future R&D and commercialization efforts. Fair value estimates suggest a 70% upside, with a base case valuation of $59.94, and even in a pessimistic scenario, the stock appears fairly valued. Due to dependence on WAKIX, I recommend a cautious 0.5x position, with potential adjustments based on upcoming trial results and stock performance. Read the full article on Seeking AlphaAnaliz Makalesi • Feb 28
Harmony Biosciences Holdings, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Shareholders might have noticed that Harmony Biosciences Holdings, Inc. ( NASDAQ:HRMY ) filed its full-year result this...Analiz Makalesi • Feb 15
Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) Shares Not Telling The Full Story
It's not a stretch to say that Harmony Biosciences Holdings, Inc.'s ( NASDAQ:HRMY ) price-to-earnings (or "P/E") ratio...Seeking Alpha • Jan 24
Harmony Biosciences: Don't Sleep On This Enterprising, Profitable Biotech
Summary Harmony Biosciences Holdings, Inc.'s Wakix, a first-in-class drug for narcolepsy, has shown strong revenue growth and recent label expansion to pediatric patients, with good future growth potential. Despite past challenges, including a short attack and a failed Phase 3 study, Harmony's stock has rebounded, supported by solid financials and strategic product extensions. Harmony's diversified pipeline, including new indications for pitolisant / Wakix, and other Phase 3 candidates, positions it for significant revenue growth and reduced single-asset risk. With strong financial metrics, profitability, and a well-planned growth strategy, HRMY stock is undervalued, making it a compelling “Buy” opportunity for 2025 in my view. Read the full article on Seeking AlphaSeeking Alpha • Nov 11
Harmony Biosciences: sNDA Of WAKIX Brings Additional Value Inflection Points
Summary Harmony Biosciences Holdings, Inc.'s potential expansion of WAKIX targeting patients with idiopathic hypersomnia possible with filing of sNDA expected in Q4 of 2024. Net sales of Wakix in Q3 of 2024 reached $186 million. The company surpassed $2 billion in cumulative net product revenue less than 5 years on the market, highlighting rapid growth. The global hypersomnia market industry is expected to grow to $5 billion by 2032. Read the full article on Seeking AlphaAnaliz Makalesi • Oct 31
Harmony Biosciences Holdings, Inc. Just Recorded A 19% EPS Beat: Here's What Analysts Are Forecasting Next
Harmony Biosciences Holdings, Inc. ( NASDAQ:HRMY ) came out with its quarterly results last week, and we wanted to see...Analiz Makalesi • Oct 30
Is Harmony Biosciences Holdings (NASDAQ:HRMY) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analiz Makalesi • Sep 25
Many Still Looking Away From Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)
There wouldn't be many who think Harmony Biosciences Holdings, Inc.'s ( NASDAQ:HRMY ) price-to-earnings (or "P/E...
Yeni Anlatı • Sep 11
Pitolisant HD's Innovations And Critical Expansions Set To Surge Revenue And Solidify Market Dominance
Expanding the patient base and treatment efficacy for narcolepsy with the high-dose program of pitolisant and pursuing additional indications will significantly grow future revenues.Seeking Alpha • Aug 15
Harmony Biosciences: Advancing An Expanded Pipeline
Summary Today, we are revisiting the biopharma name Harmony Biosciences for the first time in nearly a year and a half. The company is nicely profitable thanks to its flagship product WAKIX and Harmony has a solid balance sheet as well. Harmony Biosciences has made some recent acquisitions that greatly expanded its pipeline and peak sales potential. An updated analysis of Harmony Biosciences stock follows in the paragraphs below. Read the full article on Seeking AlphaAnaliz Makalesi • Jul 15
Harmony Biosciences Holdings (NASDAQ:HRMY) Has A Rock Solid Balance Sheet
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analiz Makalesi • Jun 07
Investors Holding Back On Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)
Harmony Biosciences Holdings, Inc.'s ( NASDAQ:HRMY ) price-to-earnings (or "P/E") ratio of 12.6x might make it look...Analiz Makalesi • May 03
Harmony Biosciences Holdings, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
It's been a good week for Harmony Biosciences Holdings, Inc. ( NASDAQ:HRMY ) shareholders, because the company has just...Analiz Makalesi • Apr 04
These 4 Measures Indicate That Harmony Biosciences Holdings (NASDAQ:HRMY) Is Using Debt Safely
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analiz Makalesi • Feb 09
Market Cool On Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) Earnings
Harmony Biosciences Holdings, Inc.'s ( NASDAQ:HRMY ) price-to-earnings (or "P/E") ratio of 13.1x might make it look...Hissedar Getirileri
| HRMY | US Pharmaceuticals | US Pazar | |
|---|---|---|---|
| 7D | 6.1% | 9.1% | -2.5% |
| 1Y | 12.2% | 49.3% | 19.0% |
Getiri vs. Endüstri: HRMY geçen yıl % 49.3 oranında getiri sağlayan US Pharmaceuticals sektörünün gerisinde kaldı.
Getiri vs Piyasa: HRMY geçen yıl % 19 oranında getiri sağlayan US Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| HRMY volatility | |
|---|---|
| HRMY Average Weekly Movement | 5.1% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
İstikrarlı Hisse Senedi Fiyatı: HRMY son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: HRMY 'nin haftalık oynaklığı ( 5% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2017 | 293 | Jeffrey Dayno | www.harmonybiosciences.com |
Ticari aşamada bir ilaç şirketi olan Harmony Biosciences Holdings, Inc., Amerika Birleşik Devletleri'nde nadir görülen nörolojik hastalıkları olan hastalar için tedaviler geliştirmeye ve ticarileştirmeye odaklanmaktadır. Şirket, narkolepsili yetişkin hastalarda gündüz aşırı uyku halinin tedavisi için yeni bir etki mekanizmasına sahip bir molekül olan WAKIX'i (pitolisant) sunmaktadır. Ayrıca Prader-Willi Sendromu (PWS) tedavisi için Faz 3 klinik çalışmasında; Miyotonik Distrofi (DM1) tedavisi için Faz 2 klinik çalışmasında; ve Pitolisant Gastro-Dirençli (GR) ve Pitolisant Yüksek Doz (HD) tedavisi için Faz 2 klinik çalışmalarında olan Pitolisant'ı geliştirmektedir.
Harmony Biosciences Holdings, Inc. Temel Bilgiler Özeti
| HRMY temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$2.05b |
| Kazançlar(TTM) | US$145.62m |
| Gelir(TTM) | US$899.11m |
14.1x
F/K Oranı2.3x
P/S OranıHRMY aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| HRMY gelir tablosu (TTM) | |
|---|---|
| Gelir | US$899.11m |
| Gelir Maliyeti | US$210.86m |
| Brüt Kâr | US$688.25m |
| Diğer Giderler | US$542.63m |
| Kazançlar | US$145.62m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | 2.52 |
| Brüt Marj | 76.55% |
| Net Kâr Marjı | 16.20% |
| Borç/Özkaynak Oranı | 17.4% |
HRMY uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/06/29 10:15 |
| Gün Sonu Hisse Fiyatı | 2026/06/26 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Harmony Biosciences Holdings, Inc. 16 Bu analistlerden 11, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Pete Stavropoulos | Cantor Fitzgerald & Co. |
| Charles Duncan | Cantor Fitzgerald & Co. |